You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
礼来季绩失色 新冠疗法对住院病人无效
阿思达克 10-28 09:16
美国药厂礼来(Eli Lilly)(LLY.US)第三季由於成本上升,盈利倒退3.2%至12.1亿美元。每股盈利为1.54美元,低於市场预期的1.71美元。收入上升5%至57.4亿美元,同样逊预期。

在业绩公布後礼来股价急跌6.92%,报131.9美元。

较早时礼来研发中的血清疗法,对感染新型冠状病毒的病人疗效有限。公司表示,对该实验性疗法仍然感到乐观,虽然对住院病人的疗效令人失望,但仍然有望用於预防或早期治疗。

礼来预计今年与新型冠状病毒相关的研发费用约为4亿美元,仍然预计全年收入介乎237亿至242亿美元,但警告要达到预测上限则需要从新冠疗法中取得相应的收入。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account